Date:
A CD19-specific CAR T-cell therapy with intermediate affinity for CD19 produced a response in 77% of adults with refractory disease. Overall survival was 61% at 12 months, and serious toxic effects were rare.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Each template in our ever growing studio library can be added and moved around within any page effortlessly with one click.
© 2021 tagDiv. All Rights Reserved. Made with Newspaper Theme.
